SG Americas Securities LLC Purchases 14,207 Shares of Exelixis, Inc. $EXEL

SG Americas Securities LLC increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 39.2% in the first quarter, Holdings Channel.com reports. The firm owned 50,495 shares of the biotechnology company’s stock after acquiring an additional 14,207 shares during the period. SG Americas Securities LLC’s holdings in Exelixis were worth $2,166,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 19,407 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares during the period. Focus Partners Wealth grew its stake in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. increased its holdings in Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC lifted its stake in Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 2,764 shares during the period. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Down 0.8%

NASDAQ:EXEL opened at $53.96 on Thursday. The stock’s 50 day moving average price is $50.18 and its two-hundred day moving average price is $45.80. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $55.91. The firm has a market capitalization of $13.56 billion, a price-to-earnings ratio of 17.93, a price-to-earnings-growth ratio of 1.57 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The company had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. During the same quarter last year, the firm posted $0.55 EPS. The company’s quarterly revenue was up 10.0% on a year-over-year basis. As a group, analysts anticipate that Exelixis, Inc. will post 3.16 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Stifel Nicolaus boosted their target price on Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Barclays boosted their price target on shares of Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a report on Monday, April 20th. Citizens Jmp raised their price objective on Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Wednesday, June 24th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. Finally, Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $46.87.

Insider Buying and Selling at Exelixis

In other news, CFO Christopher J. Senner sold 34,901 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the transaction, the chief financial officer owned 952,317 shares in the company, valued at approximately $47,615,850. This trade represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 32,110 shares of Exelixis stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total value of $1,599,399.10. Following the sale, the executive vice president directly owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. The trade was a 8.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 219,170 shares of company stock worth $10,620,641. 2.60% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.